Theophylline Derivatives/Selected CYP1A2 Inhibitors Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Some medicines may slow down how quickly your liver processes theophylline type medicines.

What might happen:

The amount of theophylline in your blood may increase and cause toxic side effects, which may include loss of appetite, nausea, vomiting, nervousness, agitation, headache, fast and/or irregular heartbeat, or seizures.

What you should do about this interaction:

Make sure that your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to check the amount of theophylline in your blood more often or may need to change your theophylline dose while taking a medicine that slows processing of theophylline.If you experience any loss of appetite, nausea, vomiting, nervousness, agitation, headache, fast and/or irregular heartbeat, or seizures, contact your doctor right away.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987 Oct 24;2(8565):939-41.
  • 2.Jonkman JH, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Oosterhuis B, De Noord OE, Guentert TW. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 1989 Jun; 27(6):795-802.
  • 3.Pegasys 135 PFS (interferon alfa-2a) UK summary of product characteristics. Roche Products Limited June 20, 2002.
  • 4.Pegasys (peginterferon alfa-2a) US prescribing information. Genentech USA, Inc. March, 2015.
  • 5.Intron A (interferon alfa-2b) US prescribing information. Schering Corporation May, 2018.
  • 6.Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology 1993 Jan;17(1):65-9.
  • 7.Katz A, Buskila D, Sukenik S. Oral mexiletine-theophylline interaction. Int J Cardiol 1987 Nov;17(2):227-8.
  • 8.Stanley R, Comer T, Taylor JL, Saliba D. Mexiletine-theophylline interaction. Am J Med 1989 Jun;86(6 Pt 1):733-4.
  • 9.Kessler KM, Interian A Jr, Cox M, Topaz O, De Marchena EJ, Myerburg RJ. Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline. Am Heart J 1989 Apr;117(4):964-6.
  • 10.Loi CM, Vestal RE. Effect of mexiletine on theophylline metabolism. Clin Pharmacol Ther 1990 Feb;47(2):130.
  • 11.Ueno K, Miyai K, Seki T, Kawaguchi Y. Interaction between theophylline and mexiletine. DICP 1990 May;24(5):471-2.
  • 12.Stoysich AM, Mohiuddin SM, Destache CJ, Nipper HC, Hilleman DE. Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 1991 Apr;31(4):354-7.
  • 13.Loi CM, Wei XX, Vestal RE. Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. Clin Pharmacol Ther 1991 May;49(5):571-80.
  • 14.Hurwitz A, Vacek JL, Botteron GW, Sztern MI, Hughes EM, Jayaraj A. Mexiletine effects on theophylline disposition. Clin Pharmacol Ther 1991 Sep;50(3):299-307.
  • 15.Ueno K, Miyai K, Kato M, Kawaguchi Y, Suzuki T. Mechanism of interaction between theophylline and mexiletine. DICP 1991 Jul-Aug;25(7-8):727-30.
  • 16.Loi CM, Day JD, Jue SG, Bush ED, Costello P, Dewey LV, Vestal RE. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther 1989 May;45(5):476-86.
  • 17.Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther 1987 Mar; 41(3):358-62.
  • 18.Vioxx (rofecoxib) US prescribing information. Merck & Co., Inc. May, 2016.
  • 19.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.